A Multi-institutional Open Label, Trial Evaluating the Efficacy of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma With Methylated CHFR and/or Microsatellite Instability Phenotype

Trial Profile

A Multi-institutional Open Label, Trial Evaluating the Efficacy of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma With Methylated CHFR and/or Microsatellite Instability Phenotype

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Docetaxel; Filgrastim; Pegfilgrastim
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 19 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top